Indivior CEO transition finalized as Ciaffoni takes over; articles amended for Nasdaq primary listing

Indivior Pharmaceuticals, Inc.

Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.
Mark Crossley stepped down as CEO and director; separation terms previously filed.
Shareholders approved new articles of association with changes, including annual director re-elections and shift to Nasdaq as primary exchange.
All 19 resolutions at the 2025 AGM passed by poll; voter turnout ~64%.
New articles remove LSE references and adjust meetings/proxy rules; full text filed as Exhibit 3.1.

item 5.02 item 1.01 item 5.03 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Crossley

Chief Executive Officer

INDV · Indivior Pharmaceuticals, Inc.

Effective: 2025-05-08
Successor: Joe Ciaffoni
Filed: May 8, 2025, 7:59 PM ET

Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.

Appointed

Joe Ciaffoni

Chief Executive Officer

INDV · Indivior Pharmaceuticals, Inc.

Effective: 2025-05-08
Filed: May 8, 2025, 7:59 PM ET

Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Crossley departed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..

Action: stepped down
Role: Chief Executive Officer

Exact text from the filing

Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Indivior Pharmaceuticals, Inc.: Amended articles of association to update provisions regarding general meetings, director elections, share sales, and primary listing references (effective 2025-05-08).

Change: charter amendment
Effective: 2025-05-08

Exact text from the filing

On May 8, 2025, Indivior’s shareholders approved amendments to the Company’s articles of association effective upon the conclusion of the 2025 AGM.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001625297-25-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.